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Abstract
Updated long-term, low-grade (grade 1/2) safety and quality of life (QoL) results from the randomized, double-
blind maintenance phase of the PARAMOUNT trial are reported. These results showed a low incidence of
low-grade adverse events and uncompromised QoL, demonstrating a well-tolerated safety proﬁle for long-
term pemetrexed maintenance.
Introduction: In the PARAMOUNT (“A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed
plus Best Supportive Care vs. Best Supportive Care Immediately Following Induction Treatment with Pemetrexed Plus
Cisplatin for Advanced Non-Squamous NoneSmall-Cell Lung Cancer”) trial, patients with advanced nonsquamous
nonesmall-cell lung cancer (NS-NSCLC) beneﬁted from pemetrexed maintenance therapy after induction therapy with
pemetrexed and cisplatin by extending survival, delaying disease progression, and maintaining quality of life (QoL).
However, low-grade 1 or 2 toxicities during long-term maintenance treatment may become burdensome and impact
QoL. Materials and Methods: Patients in this double-blind study (n ¼ 539), who had completed 4 induction cycles
(pemetrexed with cisplatin) without progressive disease (PD) and had an ECOG performance status of 0/1, were
randomized 2:1 to pemetrexed maintenance (500 mg/m2, day 1) plus best supportive care (BSC) or placebo plus BSC
until PD. Adverse events (by maximum Common Terminology Criteria for Adverse Events [CTCAE] grade) and QoL
(EuroQol 5-dimensional [EQ-5D] scale) were assessed. Results: A median of 4 maintenance cycles was administered
(range, pemetrexed 1-44; mean  SD 7.9  8.3; placebo 1-38; mean  SD 5.0  5.2), with 28% of pemetrexed andPresented in part in abstract form at the Annual Meeting of the European Society for
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12% of placebo patients receiving  10 maintenance cycles. The pemetrexed dose intensity was 94%. More patients
receiving pemetrexed (12%) than placebo discontinued because of possible drug-related CTCAEs (4%; P ¼ .005).
Overall, pemetrexed was associated with signiﬁcantly more (P < .05) low-grade events (grade 1/2 nausea, grade 2
anemia, edema, and neutropenia) than placebo. Overall, the incidence of low-grade fatigue, anemia, and neutropenia
decreased with long-term pemetrexed exposure; however, renal events increased across treatment arms. EQ-5D
analyses demonstrated no treatment-by-time interaction or overall treatment differences between the 2 arms.
Conclusion: PARAMOUNT demonstrated a low incidence of low-grade toxicities with long-term pemetrexed expo-
sure without compromising QoL in patients with NS-NSCLC.
Clinical Lung Cancer, Vol. 15, No. 6, 418-25 ª 2014 The Authors. Published by Elsevier Inc. All rights reserved.
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Maintenance therapy, which is initiated after 4 cycles of
platinum-based induction therapy in patients with advanced
nonesmall-cell lung cancer (NSCLC), delays disease progression,
extends survival, and maintains health-related quality of life
(QoL).1,2 Continuation maintenance therapy is the ongoing ad-
ministration of the non-platinum component of the initial
chemotherapy regimen until progressive disease (PD).3 Patients
with NSCLC who are candidates for maintenance therapy are those
without PD after induction therapy and with a good ECOG per-
formance status (PS 0/1). Patient safety and QoL are important
concerns in this clinical setting4,5 and have been evaluated as end-
points in NSCLC clinical trials investigating maintenance peme-
trexed6-10 and other agents.11-16 These studies have shown that
global QoL is maintained during long-term treatment.
Treatment with pemetrexed continuation maintenance therapy
after induction treatment with pemetrexed combined with cisplatin
signiﬁcantly reduced the risk of disease progression and death
compared with placebo (progression-free survival [PFS], hazard ratio
[HR], 0.62; 95% CI, 0.49-0.79; P < .0001; overall survival [OS],
HR, 0.78; 95% CI, 0.64-0.96; P ¼ .0195) in the advanced non-
squamous (NS)-NSCLC setting.6,8 In the PARAMOUNT trial, the
incidence of adverse events (AEs) reported at the primary database
lock to evaluate PFS was consistent with previously reported safety
proﬁles of pemetrexed as a single agent.6,8,10 Additionally, peme-
trexed was well tolerated as a maintenance treatment, with similar
EuroQol 5-dimensional (EQ-5D) scale scores between treatment
arms, suggesting preservation of QoL.7
Safety analyses from clinical trial data have generally focused on
high-grade (grade 3 or 4) and acute short-term events. Because the
occurrence of low-grade (grade 1 or 2) toxicities during long-term
maintenance therapy (eg, fatigue or nausea) may become burden-
some and compromise overall QoL, the present report has provided
an updated analysis of low-grade toxicity and QoL results of peme-
trexed maintenance compared with placebo in the PARAMOUNT
trial from the ﬁnal database lock (March 19, 2012).
Materials and Methods
Study Design and Treatment Plan
PARAMOUNT, a phase III, multicenter, randomized, double-
blind, placebo-controlled study, consisted of induction and
continuation maintenance treatment phases. Previous publicationshave provided a full description of the study design and treat-
ment plan.6,7 In brief, in the double-blind maintenance phase, 539
eligible patients (patients who had completed 4 cycles of induc-
tion therapy, had not progressed, and had an ECOG PS of 0/1)
were randomized 2:1 to pemetrexed 500 mg/m2 (ALIMTA
[LY231514], Eli Lilly and Company, Indianapolis, IN) plus best
supportive care (BSC) or placebo plus BSC. BSC was administered
at the discretion of the physician and was designed to alleviate
patient symptoms by methods other than prescribed antineoplastic
agents. All patients received vitamin B12 and folic acid supple-
mentation and prophylactic dexamethasone during the induction
and maintenance treatment phases. Treatment delays were
permitted for  42 days to allow sufﬁcient time for recovery from
study drug-related toxicity.8
Patients discontinued maintenance therapy at the occurrence of
disease progression, unacceptable toxicity, or at the on request of the
patient or physician. All patients were followed up until death or
study closure.
Statistical Analysis
The primary and secondary endpoint results from the PARA-
MOUNT trial (ie, PFS, OS, tumor response rate, patient-reported
outcomes using the EQ-5D QoL tool, resource use, and toxicity)
were previously published.6-8 The long-term safety, resource use,
and patient-reported QoL data from the ﬁnal database lock have
been updated in the present study.
The mean pemetrexed dose was calculated as the overall
dose administered divided by the treatment duration. The planned
dose divided by the treatment duration yielded the planned
mean pemetrexed dose. The pemetrexed weekly dose intensity
was calculated as follows: (actual mean dose/planned mean
dose)  100%.
Patients were included in the safety analysis if they had been
randomized to the maintenance phase and treated with  1 dose of
pemetrexed or placebo. Safety was summarized for all randomized
patients by treatment group as follows: the incidence of possible
study drug-related Common Terminology Criteria for Adverse
Events (CTCAE, version 3.0), treatment discontinuation, and dose
delays occurring in all cycles of maintenance therapy. Additionally,
we evaluated the incidence of selected clinically relevant, possible
study drug-related events commonly associated with pemetrexed
treatment (ie, anemia, fatigue, neutropenia, and renal events) duringClinical Lung Cancer November 2014 - 419
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420 -maintenance cycles 1 through 11. Additional analyses are presented
for fatigue.
The patient-reported EQ-5D QoL analysis included all patients
who had provided a baseline assessment and  1 subsequent
assessment. The EQ-5D QoL instrument has been previously
described.17,18 The UK index score is generated from the 5 des-
criptive questions in the EQ-5D QoL questionnaire related to
mobility, self-care, usual activities, pain or discomfort, and anxiety
or depression. The visual analog scale (VAS) is the part of the
instrument that allows patients to rate their present health on a
scale from 0 to 100. The UK index and VAS scores were analyzed
using a mixed-effects analysis of variance model. The mean
changes from baseline by treatment group were compared at each
maintenance cycle using the paired t test. The changes in ECOG
PS from baseline were assessed by treatment group, the same as in
a previous publication.7
Results
Patient Characteristics
The baseline patient and disease characteristics were well
balanced between the treatment arms. The median age was 60 years
in the pemetrexed maintenance arm and 62 years in the placebo
arm. Most patients were male (pemetrexed 56%; placebo 62%),
white (pemetrexed 94%; placebo 95%), had stage IV disease
(pemetrexed 91%; placebo 90%), and reported a history of smoking
(pemetrexed 76%; placebo 80%). Most patients had an ECOG PS
of 1 (pemetrexed 69%; placebo 67%) and stable disease after in-
duction therapy (pemetrexed 53%; placebo 53%).
The patients were randomized 2:1 to either pemetrexed 500 mg/m2
plus BSC (n ¼ 359) or placebo plus BSC (n ¼ 180) maintenanceFigure 1 Summary of Maintenance Cycles Administered. The Perce
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Clinical Lung Cancer November 2014therapy. A median number of 4 maintenance cycles was administered
in both treatment arms (pemetrexed, range, 1-44, mean  SD,
7.9  8.3; placebo range, 1-38, mean  SD, 5.0  5.2). The
pemetrexed dose intensity was 94%. As summarized in Figure 1,
28% of the patients in the pemetrexed arm received  10 cycles of
maintenance therapy (ie, a total of  14 pemetrexed cycles, which
included 4 cycles of pemetrexed combined with cisplatin as induction
therapy [data not shown]). In the placebo arm, 12% of patients
received  10 maintenance cycles. As expected, the number of
randomized patients who received maintenance therapy progressively
declined with each cycle. At the ﬁnal data cutoff date, the median
follow-up period for the entire population was 12.5 months (95%
CI, 11.1-13.7) and 24.3 months (95% CI, 23.2-25.1) for alive
patients.
Safety
The incidence of possible study drug-related CTCAE toxicity by
grade occurring in all cycles of maintenance therapy stratiﬁed by
treatment arm is listed in Table 1. Overall, the incidence of any
grade 1 CTCAE was similar between treatment arms (pemetrexed
14.8%; placebo 13.3%). Nausea was the only grade 1 toxicity with
a signiﬁcantly greater incidence in the pemetrexed arm than in the
placebo arm (8.9% vs. 1.1%, respectively; P < .001). The overall
incidence of grade 2 CTCAEs was signiﬁcantly greater in the
pemetrexed arm than in the placebo arm (23.4% vs. 12.8%,
respectively; P < .01), and the incidence of nausea, anemia, edema,
and neutropenia was signiﬁcantly greater in the pemetrexed arm
than in the placebo arm (P < .05 for all).
The incidence of other common low-grade toxicities, such as
rash, mucositis/stomatitis, and conjunctivitis, did not signiﬁcantlyntage of Randomized Patients Per Maintenance Cycle (Cycles
(> 1%) Were Rounded to the Nearest Whole Number
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Table 1 Study Drug-Related Adverse Eventsa by Maximum CTCAE Toxicity Grade Occurring in ‡ 2% of Patients During Maintenance
Therapy (Cycles 1-44)
CTCAE
Pemetrexed (n [ 359) Placebo (n [ 180)
Grade 1 (%) Grade 2 (%) Grade 3/4 (%) Grade 1 (%) Grade 2 (%) Grade 3/4 (%)
Any CTCAE 14.8 23.4b 11.7c 13.3 12.8 4.5
Fatigue 8.9 9.7 5.3c 5.6 5.0 1.1
Nausea 8.9b 5.8b 0.6 1.1 1.1 0.0
Anemia 4.2 10.0b 6.7c 1.1 3.3 0.6
Edema 4.2 3.6b 0.0 3.3 0.0 0.0
Mucositis/stomatitis 3.9 2.2 0.6 1.1 1.1 0.0
Neuropathy/sensory 4.5 0.6 0.6 5.0 1.1 0.6
Neutropenia 1.9 3.6b 6.1c 0.0 0.6 0.0
Leukopenia 1.4 1.7 2.2 0.0 0.0 0.0
ALT (SGPT) 0.8 1.7 0.3 0.0 0.6 0.0
Renal toxicities 3.1 3.9 0.8 1.7 0.6 0.0
Rash 2.2 0.6 0.0 2.2 0.0 0.0
Conjunctivitis 0.6 0.8 0.0 0.0 0.0 0.0
Abbreviations: ALT ¼ alanine aminotransferase; CTCAE ¼ Common Terminology Criteria for Adverse Events; SGPT ¼ serum glutamic pyruvic transaminase.
aEvents starting during induction remaining and ongoing during maintenance therapy without any change in severity were excluded.
bStatistical signiﬁcance limit of P < .05 versus placebo.
cStatistical signiﬁcance limit of P < .05 versus placebo for grade 3 only.
Jean-Louis Pujol et aldiffer between the treatment arms (Table 1). The overall incidence
of CTCAE grade 3/4 was greater in the pemetrexed arm than in the
placebo arm (11.7% vs. 4.5%, respectively; Table 1). Most of these
events were grade 3 (pemetrexed 10.6%; placebo 2.8%; P ¼ .001),
and the incidence of grade 4 events was both low and similar be-
tween treatment arms (pemetrexed 1.1%; placebo 1.7%). The
incidence of grade 3/4 fatigue, anemia, and neutropenia was
signiﬁcantly greater in the pemetrexed arm than in the placebo arm.
Figure 2 presents the incidence of possible study drug-related
CTCAE toxicity (by cycle) for neutropenia, renal, anemia, and fa-
tigue events (all grades) in cycles 1 through 11. At any given
cycle, < 15% of patients in the pemetrexed arm experienced any of
the speciﬁed grade 1 or 2 events.
For neutropenia, the overall incidence of grade 1 or 2 events was
low ( 3%) in both treatment arms (P > .05 for all; Figure 2A).
Renal toxicity was experienced by < 6% of the patients in both
treatment arms, and the difference was not statistically signiﬁcant.
Unlike other toxicities, the incidence of grade 1 renal toxicity
events increased with the number of maintenance cycles in both
treatment arms (Figure 2B), although the differences were not
signiﬁcant. The incidence of grade 2 anemia was signiﬁcantly
greater with pemetrexed than with placebo in cycles 2 and 3
(10.1% vs. 4.3% and 7.9% vs. 1.8%, respectively; P < .05 for all),
followed by a decreasing trend. In contrast, an increasing trend of
grade 2 anemia was seen in the placebo arm from cycles 3 to 11
(Figure 2C).
Fatigue was the most frequently reported any grade toxicity
(23.9% vs. 11.7% for pemetrexed vs. placebo, respectively;
P < .001). The incidence of grade 1/2 fatigue ranged from 6.7% to
14.5% for pemetrexed and 0% to 12.5% for placebo in cycles 1
through 11 (Figure 2D). Compared with placebo, the patients in
the pemetrexed arm experienced signiﬁcantly more grade 1 fatigue
at cycles 4, 5, 6, and 8 (P < .05 for all). However, 8.9% and 12.2%
of patients assigned to the pemetrexed and placebo arms,respectively, had fatigue as a prerandomization condition, implying
that these patients had ﬁrst experienced fatigue in the induction
phase (data not shown).
The onset of fatigue, regardless of causality, was further investi-
gated (Figure 3). Of the pemetrexed-treated patients who reported
any grade of fatigue during the study period, most (74%) had ﬁrst
experienced fatigue during the induction phase. Only 26% of the
patients reported fatigue onset during the maintenance phase. In
addition, most patients experienced the onset and maximum grade
of fatigue in the same cycle, primarily during the induction phase
(data not shown).
Treatment Discontinuation
A similar percentage of pemetrexed- and placebo-treated patients
discontinued maintenance treatment (97.5% and 98.9%, respec-
tively; Table 2). Fewer patients in the pemetrexed arm discontinued
treatment because of PD than did patients in the placebo arm
(69.4% vs. 84.4%, respectively). A signiﬁcantly greater percentage
of patients in the pemetrexed arm than in the placebo arm dis-
continued treatment because of possible study drug-related
CTCAEs (12.0% vs. 4.4%, respectively; P ¼ .005; Table 2). Pa-
tients discontinued treatment because of CTCAEs of grade 1/2
(pemetrexed 6.4%; placebo 1.7%), grade 3/4 (pemetrexed 5.3%;
placebo 1.7%), and grade 5 (pemetrexed 0.3%; placebo 1.1%). Of
the 43 patients who discontinued pemetrexed, more than one half
(61%) discontinued during cycles 1 through 6 (data not shown).
Renal toxicity was the most commonly reported possible study
drug-related event leading to discontinuation (n ¼ 16 [4.5%];
n ¼ 13, grade 1/2, and n ¼ 3, grade 3 events), of which only
1 event was reported as serious. The second-most common event
leading to discontinuation was asthenia/fatigue (n ¼ 8 [2.2%];
3 with grade 1/2 and 5 with grade 3), of which none were
considered serious. In the placebo arm, 1 patient each (0.6%) dis-
continued because of an event related to renal function and fatigue.Clinical Lung Cancer November 2014 - 421
Figure 2 Possible Study Drug-Related Common Terminology Criteria for Adverse Events (CTCAE) Toxicity by Maintenance Cycle.
Incidence of (A) Neutropenia, (B) Renal, (C) Anemia, and (D) Fatigue Events by Grade for Patients in Each Group (Pemetrexed
[PEM], n [ 357; Placebo, n [ 178) for Maintenance Cycles 1 Through 11. P < .01 and yP < .05 for Pemetrexed Grade
Speciﬁed versus Corresponding Placebo Grade
Abbreviation: Gr ¼ grade.
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422 -Dose Delays
More patients in the pemetrexed maintenance arm than in the
placebo arm experienced dose delays due to possible study drug-
related CTCAEs (18.7% vs. 11.1%, respectively). The most
common CTCAEs leading to those delays in the pemetrexed
versus placebo arms, respectively, were anemia/hemoglobin de-
crease (5.6% vs. 1.7%), neutropenia (4.5% vs. 3.9%), events
associated with renal function (2.8% vs. 1.7%), and asthenia/
fatigue (2.5% vs. 0.6%).
Resource Utilization
In general, the use of supportive care was greater in the peme-
trexed arm than in the placebo arm. The percentage of patients who
received red blood cell (RBC) transfusions was signiﬁcantly greater
in the pemetrexed arm than in the placebo arm (16.2% vs. 5.6%;
P< .001). The use of other transfusions, such as plasma or platelets,
was not signiﬁcantly different between the 2 treatment arms. InClinical Lung Cancer November 2014addition, more patients in the pemetrexed arm than in the placebo
arm received concomitant antibiotics during maintenance therapy
(30.1% vs. 18.9%, respectively; P ¼ .005). Concomitant use of
granulocyte or granulocyte macrophage colony-stimulating factor
(CSF) was 7.0% in the pemetrexed arm and 0.6% in the placebo
arm (P < .001). The percentage of patients with  1 hospitalization
was similar for both treatment arms (24.8% vs. 20.0%). However,
signiﬁcantly more patients in the pemetrexed arm than in the pla-
cebo arm were hospitalized because of study drug-related CTCAEs
(10.9% vs. 3.3%; P ¼ .003).
ECOG PS
Overall, the PS changes in the pemetrexed and placebo treatment
arms did not differ signiﬁcantly. Most patients in both treatment
arms were able to maintain their PS from the baseline assessment at
randomization throughout the maintenance phase (pemetrexed
76% vs. placebo 79%). Likewise, the balance was equal between
Table 3 Quality of Life Update: Repeated Measures Analysis
of UK Index and VAS Scores (EQ-5D) During
Maintenance Therapy
Quality of Life Parameters
Overall P Value
Between Treatment
Groups
Interaction
P Valuea
Mobility .090 .475
Self-care .003 .614
Usual activities .051 .553
Pain/discomfort .964 .374
Anxiety/depression .851 .739
VAS health state score .515 .977
UK population-based index score .241 .770
Abbreviations: EQ-5D ¼ EuroQoL 5-dimensional; UK ¼ United Kingdom; VAS ¼ visual analog
scale.
aP value for treatment by cycle interaction.
Figure 3 Onset of Fatigue. Percentage of Randomized Patients
With Onset of Fatigue (Any Grade), Regardless of
Causality, During Induction and Continuation
Maintenance Phases. Of 359 Patients Randomized to
Pemetrexed (PEM) Maintenance and 180 Randomized
to Placebo, 7 (2%) and 1 (1%) Developed Fatigue
Onset Beyond Cycle 11 Through the End of the Study
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Jean-Louis Pujol et altreatment arms for both improvements in PS from baseline
(pemetrexed 8%; placebo 9%) and worsened PS (pemetrexed 16%;
placebo 12%). Overall, 32.1% of all patients had a PS of 0%
and 67.3% a PS of 1 at baseline; 12.1% of those patients improved
to a PS of 0.
Quality of Life
The updated EQ-5D measures, including the UK index and VAS
scores, from the ﬁnal data cutoff date are listed in Table 3. The
overall P value was used to compare the difference in the average
change from the baseline QoL parameters between the treatment
arms. The interaction P value was used to measure whether theTable 2 Reasons for Treatment Discontinuation From
Maintenance Therapy
Reasons for Discontinuation
Pemetrexed
(n [ 359)
Placebo
(n [ 180)
All randomized patients 97.5 98.9
Progressive disease 69.4 84.4
Adverse event
Regardless of cause 19.5a 8.3
Possible study drug-related 12.0a 4.4
Serious adverse event
Regardless of cause 6.7 2.8
Possibly study drug-related 3.3 1.7
Investigator decision 0.8 1.1
Subject decision 5.8 4.4
Death 2.2 2.2
Study disease 0.8 0.6
Adverse event/toxicity 1.1 0.6
Study drug-related 0.3 1.1
Data presented as %.
aStatistical signiﬁcance limit of P < .01 versus placebo.pemetrexed and placebo proﬁles differed over time. All interaction
term P values were > .05, demonstrating that the QoL parameters
for the pemetrexed and placebo treatment arms did not signiﬁcantly
differ from randomization through the last assessment after treat-
ment discontinuation. Although the mean scores for 2 individual
parameters (self-care and usual activities) favored pemetrexed over
placebo, no statistically signiﬁcant differences were observed in the
patient-reported QoL measures.
Discussion
The safety data reported for maintenance studies have generally
been limited to the incidence of high-grade (grade 3/4) toxic-
ities.3,10,12,14,19,20 However, the incidence of low-grade (grade 1/2)
toxicities is equally important during long-term maintenance
treatment because these events may impact health-related QoL and
the ability of patients to continue treatment. To our knowledge,
PARAMOUNT is the only trial that reports both grade 1/2 and 3/4
toxicities, making it difﬁcult to effectively compare the incidence of
grade 1/2 toxicities across studies.
In the present analysis, the overall low incidence ( 10%) of
grade 1 or 2 events commonly associated with pemetrexed main-
tenance treatment included gastrointestinal, fatigue, and hemato-
logic toxicities. The grade 3/4 incidence of these same events
was < 7% (Table 1). Other clinically relevant toxicities associated
with pemetrexed (skin and renal events) were less frequent, pri-
marily low-grade, and comparable between the treatment arms.
When comparing 2 chemotherapy agents evaluated in the mainte-
nance setting, pemetrexed and gemcitabine, the incidence of
low-grade fatigue, anemia, neutropenia, and rash observed with
pemetrexed was numerically lower than that reported for
gemcitabine.20
The percentage of patients receiving  10 cycles of maintenance
in the pemetrexed arm (28%) demonstrated that maintenance
therapy was well tolerated for an extended period. The discontin-
uation rate because of possible study drug-related CTCAEs was
nearly 3 times greater in the pemetrexed arm (12.0%) than in the
placebo arm (4.4%). The most common event leading to discon-
tinuation from the pemetrexed arm was grade 1/2 renal events
(3.6%). More than one half of the discontinuations in theClinical Lung Cancer November 2014 - 423
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424 -pemetrexed arm were due to low-grade events and occurred within
the ﬁrst 6 cycles, suggesting that discontinuation is likely to occur
earlier, rather than later. No evidence was found that long-term
(> 6 cycles) maintenance treatment will lead to an increased dis-
continuation rate because of drug-related events (cumulative effect).
Although direct comparisons could not be made between the safety
proﬁles of drugs with different mechanisms of action, such as a
chemotherapy and epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), a trial investigating maintenance erlotinib
(an EGFR-TKI) compared with placebo reported a similar differ-
ence in discontinuation rates between the 2 arms (5% vs. 2%,
respectively; 2.5 times more discontinuations with the active
treatment).14
Clinically relevant CTCAEs associated with pemetrexed treat-
ment in the ﬁrst 11 maintenance cycles were further explored in an
analysis by cycle (Figure 2). Toxicities occurring beyond mainte-
nance cycle 11 were not assessed due to the low number of patients
receiving > 10 cycles, particularly in the placebo arm (Figure 1).
Although the incidence of low-grade toxicities was signiﬁcantly
greater among patients receiving pemetrexed (grade 2 anemia and
grade 1 fatigue) at the early maintenance cycles, the patients who
continued pemetrexed for > 6 cycles reported neutropenia and
anemia less frequently. This could have resulted from either earlier
discontinuation of maintenance therapy for the subgroup of pa-
tients affected by toxicity and/or overall adequate management of
anemia and neutropenia, resulting in an increased number of RBC
transfusions and the use of CSF in the pemetrexed arm. Unlike
other toxicities (eg, anemia, fatigue, and neutropenia), relatively
small increases the incidence of in low-grade renal events were
observed in the ﬁrst 11 maintenance cycles. However, the inci-
dence of renal-related events was not statistically different in pa-
tients receiving pemetrexed versus those receiving placebo, either
in the ﬁrst 11 cycles or across all maintenance cycles. In addition,
the analysis of patient outcomes after renal events in the PARA-
MOUNT study suggested that a clinically signiﬁcant majority of
patients receiving pemetrexed with mild-to-moderate renal
dysfunction were able to recover (data not shown). As expected,
the type, grade, and incidence of any AE observed in the present
study were not signiﬁcantly affected by maintenance therapy,
further supporting pemetrexed use as long-term, single-agent
therapy for patients with advanced NS-NSCLC.
From a patient’s and clinician’s perspective, cancer-related fa-
tigue is one of the most common and distressing adverse effects of
cancer treatment and can signiﬁcantly stress and impair a patient’s
daily performance.21 Fatigue was the most commonly reported
study drug-related toxicity during PARAMOUNT maintenance
treatment. In randomized patients who experienced fatigue during
the study, we further assessed whether fatigue was ﬁrst experi-
enced in the induction or maintenance phase (Figure 3). Differ-
entiating the occurrence of AEs by phase of onset can be
informative to fully characterize the safety proﬁle during the
maintenance phase.19 Within the patient population randomized
to pemetrexed who experienced any grade of fatigue, regardless of
causality, during the induction and/or maintenance phases, only
26% ﬁrst experienced fatigue as a new event during the mainte-
nance phase.Clinical Lung Cancer November 2014Dose delays due to possible study drug-related CTCAEs were
numerically greater with pemetrexed; however, no clinically or
statistically signiﬁcant differences were observed compared with
placebo. This was an expected ﬁnding in a study comparing an
active cytotoxic agent against placebo.
Resource use during continuation maintenance therapy was
consistent with observations from a previous report of resource use
in PARAMOUNT.7 The use of RBC transfusions, antibiotics, and
CSF, as well as hospitalizations due to study drug-related CTCAEs,
was signiﬁcantly greater in the pemetrexed maintenance arm than in
the placebo arm, although the magnitude of the differences between
treatments was small (6%-11%).
In our previously published EQ-5D results, no overall treatment
differences in QoL were observed between the pemetrexed and
placebo arms.7 Repeated measures analyses showed no treatment-
by-time interaction and no overall treatment differences between
arms; these ﬁnal data support the initial PARAMOUNT QoL re-
sults (Table 3). The EQ-5D QoL proﬁles were similar between the
treatment arms and correlated with similar changes in the ECOG
PS from baseline in the pemetrexed and placebo arms. Overall, the
PARAMOUNT trial demonstrated that pemetrexed maintenance
after pemetrexed and cisplatin induction therapy signiﬁcantly im-
proves both OS and PFS,6 with a long-term safety proﬁle that does
not compromise the QoL of patients with advanced NS-NSCLC.
The low-grade safety results we have presented further support
long-term treatment with pemetrexed in the continuation mainte-
nance clinical setting.
Conclusion
The present updated long-term safety report included data from
the ﬁnal database lock and offers supportive safety evidence of
pemetrexed maintenance therapy after pemetrexed combined with
cisplatin ﬁrst-line induction therapy in patients with advanced
NS-NSCLC, with a low incidence of the grade 1/2 and 3/4
CTCAEs generally associated with pemetrexed. For any speciﬁc
toxicity type,  10% of patients randomized to pemetrexed expe-
rienced grade 1 or 2 events during maintenance therapy. As ex-
pected, a greater incidence of CTCAEs occurred with pemetrexed
than with placebo. However, overall tolerability was not affected by
long-term pemetrexed maintenance therapy, and patient QoL and
PS were preserved. Overall, the PARAMOUNT trial has shown that
pemetrexed continuation maintenance therapy is clinically beneﬁ-
cial to patients by prolonging survival6,8 and does not pose any
signiﬁcant safety concerns, even when administered as long-term
treatment.
Clinical Practice Points
 Continuation maintenance therapy has been associated with
delayed disease progression and prolonged survival in patients
with advanced NSCLC who have not experienced disease
progressed after induction treatment and who have a good
ECOG PS.1,2
 In PARAMOUNT, pemetrexed maintenance therapy signiﬁ-
cantly reduced the risk of disease progression and improved
survival compared with placebo,6 patient QoL was not
compromised, and patients were able to maintain their PS.7
Jean-Louis Pujol et al Overall, pemetrexed maintenance offers a favorable risk/beneﬁt
proﬁle for patients with NS-NSCLC, with improved survival
beneﬁts and no unexpected safety concerns.
 Pemetrexed maintenance treatment was well tolerated, and the
toxicities were consistent with previously reported safety
proﬁles.6,8,10
 The low incidence of low- and high-grade toxicity events
observed with long-term administration of pemetrexed mainte-
nance therapy further validates the safety and tolerability of
pemetrexed in a continuation maintenance clinical setting.Acknowledgments
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